NEEDHAM, Mass. -- AVANT Immunotherapeutics Inc. has signed an extended collaborative research and development agreement with Pfizer Inc aimed at the discovery and development of vaccines to protect animals.



The collaboration will employ vaccine technologies owned by AVANT.



Under the agreement, Pfizer and AVANT will conduct a joint research program funded by Pfizer to develop prophylactic and therapeutic vaccines to protect livestock and companion animals from respiratory and enteric diseases. Financial terms were not disclosed.



"We are very pleased to extend our collaboration with Pfizer to leverage the value of AVANT's vaccine technology in a significant market opportunity outside AVANT's own focus on human health care," said Una S. Ryan, resident and CEO of AVANT Immunotherapeutics Inc.



Pfizer Animal Health is a leader in the global industry.



AVANT Immunotherapeutics Inc. discovers and develops innovative vaccines and therapeutics that harness the human immune system to prevent and treat disease.



SOURCE: AVANT Immunotherapeutics Inc. via Business Wire.